Iambic Therapeutics (IAM)
Market Price (11/5/2026): $12.2 | Market Cap: $578.3 MilSector: Health Care | Industry: Biotechnology
Iambic Therapeutics (IAM)
Market Price (11/5/2026): $12.2Market Cap: $578.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Precision Medicine, and Artificial Intelligence. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Stock price has recently run up significantly6M Rtn6 month market price return is 13399900%, 12M Rtn12 month market price return is 13399900% High stock price volatilityVol 12M is 20864326% Key risksIAM key risks include [1] the potential clinical or regulatory failure of its lead drug candidate, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Artificial Intelligence. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Stock price has recently run up significantly6M Rtn6 month market price return is 13399900%, 12M Rtn12 month market price return is 13399900% |
| High stock price volatilityVol 12M is 20864326% |
| Key risksIAM key risks include [1] the potential clinical or regulatory failure of its lead drug candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Iambic Therapeutics (IAM) stock has gained about 9223372036854775803% since 7/31/2026 because of the following key factors:
1. Reverse Stock Split and Initial Public Offering (IPO). Iambic Therapeutics executed a one-for-5.2587 reverse stock split on October 7, 2026, which significantly increased its share price by reducing the number of outstanding shares. This was immediately followed by the company's Initial Public Offering (IPO) on October 14, 2026, with shares commencing public trading on Nasdaq under the symbol IAM on October 15, 2026. The IPO priced at $16.00 per share, raising $150 million, and the stock closed approximately 18% higher at $18.91 on its first day of trading. This combination of events fundamentally changed the company's market valuation from a private entity to a publicly traded one, directly contributing to the reported percentage gain from its pre-IPO, pre-split status.
2. Proprietary AI-Driven Drug Discovery Platform. Investor interest was significantly fueled by Iambic Therapeutics' "molecular superintelligence" platform, which integrates proprietary AI models (Enchant and NeuralPLexer) with automated laboratory experimentation. This advanced AI approach is positioned to accelerate drug discovery and development, aiming to disrupt traditional biopharmaceutical paradigms and improve the success rates of finding new medicines.
Show more
Iambic Therapeutics (IAM) stock has gained about 9223372036854775803% since 7/31/2026 because of the following key factors:
1. Reverse Stock Split and Initial Public Offering (IPO). Iambic Therapeutics executed a one-for-5.2587 reverse stock split on October 7, 2026, which significantly increased its share price by reducing the number of outstanding shares. This was immediately followed by the company's Initial Public Offering (IPO) on October 14, 2026, with shares commencing public trading on Nasdaq under the symbol IAM on October 15, 2026. The IPO priced at $16.00 per share, raising $150 million, and the stock closed approximately 18% higher at $18.91 on its first day of trading. This combination of events fundamentally changed the company's market valuation from a private entity to a publicly traded one, directly contributing to the reported percentage gain from its pre-IPO, pre-split status.
2. Proprietary AI-Driven Drug Discovery Platform. Investor interest was significantly fueled by Iambic Therapeutics' "molecular superintelligence" platform, which integrates proprietary AI models (Enchant and NeuralPLexer) with automated laboratory experimentation. This advanced AI approach is positioned to accelerate drug discovery and development, aiming to disrupt traditional biopharmaceutical paradigms and improve the success rates of finding new medicines.
3. Advancement of Oncology Pipeline with Positive Clinical Data. The company reported favorable clinical progress for its lead oncology programs during fiscal Q4 2026. Updated clinical data for IAM1363, a HER2 inhibitor currently in a Phase 1/1b trial, was presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23, 2026. The data demonstrated durable anti-tumor activity, intracranial responses, and a favorable tolerability profile in heavily pretreated participants with HER2-altered advanced cancers. Furthermore, the company submitted an Investigational New Drug (IND) application for IAM217 (a KIF18A inhibitor) in fiscal Q4 2026 and anticipates submitting an IND for IAM-C1 (a CDK2/4 inhibitor) also in fiscal Q4 2026, with plans to initiate Phase 1/2 clinical trials for both.
4. Substantial Funding and Strategic Pharmaceutical Partnerships. Iambic Therapeutics successfully secured significant capital, raising approximately $461.8 million from its inception through September 18, 2026. Complementing this, the company established high-profile collaborations with major pharmaceutical entities such as AbbVie, Takeda, and Lundbeck. These partnerships include potential milestone payments totaling up to $1.7 billion, which validates Iambic's technological platform and provides crucial financial resources for its pipeline development.
Show less
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
7/31/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| IAM | ∞% | |
| Market (SPY) | 2.6% | 9.6% |
| Sector (XLV) | 16.7% | 27.3% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| IAM | 13399900.0% | |
| Market (SPY) | 7.0% | � |
| Sector (XLV) | 30.5% | � |
Fundamental Drivers
nullnull
Market Drivers
10/31/2025 to 11/4/2026| Return | Correlation | |
|---|---|---|
| IAM | 13399900.0% | |
| Market (SPY) | 13.4% | � |
| Sector (XLV) | 33.2% | � |
Fundamental Drivers
nullnull
Market Drivers
10/31/2023 to 11/4/2026| Return | Correlation | |
|---|---|---|
| IAM | 744344.4% | |
| Market (SPY) | 89.7% | � |
| Sector (XLV) | 59.5% | � |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IAM Return | -78% | -100% | -97% | -75% | 0% | 13399900% | -32% |
| Peers Return | -42% | -45% | 12% | -46% | 12% | 90% | -59% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| IAM Win Rate | 8% | 17% | 33% | 8% | 9% | 11% | |
| Peers Win Rate | 36% | 38% | 50% | 33% | 55% | 58% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| IAM Max Drawdown | -80% | -100% | -99% | -100% | -100% | -100% | |
| Peers Max Drawdown | -62% | -62% | -64% | -59% | -51% | -42% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SDGR, RXRX, RLAY, CERT, ABCL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/4/2026 (YTD)
How Low Can It Go
| Event | IAM | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -100.0% | -18.8% |
| % Gain to Breakeven | ∞% | 23.1% |
| Time to Breakeven | 591 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -55.3% | -9.5% |
| % Gain to Breakeven | 123.5% | 10.5% |
| Time to Breakeven | 1078 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -70.5% | -6.7% |
| % Gain to Breakeven | 239.3% | 7.1% |
| Time to Breakeven | 1231 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -99.4% | -24.5% |
| % Gain to Breakeven | 17100.0% | 32.4% |
| Time to Breakeven | 1455 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -39.1% | -33.7% |
| % Gain to Breakeven | 64.3% | 50.9% |
| Time to Breakeven | 34 days | 140 days |
In The Past
Iambic Therapeutics's stock fell null during the 2025 US Tariff Shock. Such a loss loss requires a 9.2233720368547763E17% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | IAM | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -100.0% | -18.8% |
| % Gain to Breakeven | ∞% | 23.1% |
| Time to Breakeven | 591 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -55.3% | -9.5% |
| % Gain to Breakeven | 123.5% | 10.5% |
| Time to Breakeven | 1078 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -70.5% | -6.7% |
| % Gain to Breakeven | 239.3% | 7.1% |
| Time to Breakeven | 1231 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -99.4% | -24.5% |
| % Gain to Breakeven | 17100.0% | 32.4% |
| Time to Breakeven | 1455 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -39.1% | -33.7% |
| % Gain to Breakeven | 64.3% | 50.9% |
| Time to Breakeven | 34 days | 140 days |
In The Past
Iambic Therapeutics's stock fell null during the 2025 US Tariff Shock. Such a loss loss requires a 9.2233720368547763E17% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Iambic Therapeutics (IAM)
Iambic Therapeutics (IAM) is a clinical-stage biotechnology company specializing in the discovery and development of novel small molecule therapeutics, primarily for oncology. The company distinguishes itself through its proprietary artificial intelligence (AI) platform, which is integral to accelerating the design and optimization of highly potent and selective drug candidates. By leveraging AI from the earliest stages of drug discovery, Iambic aims to create precision medicines that address significant unmet needs in cancer treatment, potentially leading to more effective and safer therapies than current standards.
Iambic's core "product" is its AI-driven drug discovery engine, which generates its pipeline. Their lead product in development is IAM-1363, a pan-variant HER2 inhibitor currently in clinical trials for various solid tumors, demonstrating their focus on overcoming resistance mechanisms in cancer. The company's pipeline also includes other preclinical programs targeting challenging oncogenic pathways. Iambic Therapeutics primarily serves the global oncology market, with its ultimate beneficiaries being cancer patients, particularly those with HER2-driven cancers or other specific oncogenic mutations. Healthcare providers and hospitals would be the primary channels for their therapies, positioning Iambic within the broader pharmaceutical and biotechnology industry as an innovator in targeted cancer treatments.
AI Analysis | Feedback
AI Analysis | Feedback
Here are the major products of Iambic Therapeutics:
- IAM-1363: A pan-RAF inhibitor currently in clinical trials for solid tumors, designed to target various RAF-mutated cancers.
- IAM-0205: A selective CDK2 inhibitor currently in clinical trials for CDK2-addicted tumors, including specific types of breast cancer.
- Discovery Programs: Early-stage drug candidates leveraging their AI-driven platform to identify novel therapies for challenging cancer targets.
AI Analysis | Feedback
AI Analysis | Feedback
- Google LLC (subsidiary of Alphabet Inc. GOOGL)
AI Analysis | Feedback
Tom Miller, PhD Co-Founder and Chief Executive Officer
Tom Miller is a scientist and entrepreneur focused on the intersection of AI, chemistry, and biology, and has served as the Co-founder and Chief Executive Officer of Iambic Therapeutics since 2020. Prior to co-founding Iambic in 2019, he was a tenured professor at the California Institute of Technology (Caltech) for over 10 years, where his work focused on the confluence of AI and biology. During his time at Caltech, he published more than 140 peer-reviewed articles and patents and received numerous awards for research and entrepreneurial excellence. Dr. Miller earned a B.S. in Chemistry and Mathematics from Texas A&M University and a Ph.D. in Theoretical Chemistry from the University of Oxford. He also serves on the board of directors at Veracyte.
Michael Secora, PhD Chief Financial Officer and Chief Corporate Development Officer
Michael Secora was appointed Chief Corporate Development Officer and Chief Financial Officer of Iambic Therapeutics in January 2025. In this role, he leads the company's finance and corporate development activities. Before joining Iambic, Dr. Secora served as the CFO and Executive Leader of Value Translation at Recursion. He is recognized for his leadership in defining the value proposition for technology-driven drug development, leveraging his expertise in science, capital markets, and business.
Fred Manby, PhD Co-Founder and Chief Technology Officer
Fred Manby is the Co-Founder and Chief Technology Officer of Iambic Therapeutics, which he co-founded in 2019. His academic career largely involved exploring the application of AI to small molecule drug discovery at the University of Bristol in the U.K.
Neil Josephson, MD Chief Medical Officer
Neil Josephson serves as the Chief Medical Officer at Iambic Therapeutics. His professional background includes extensive publications in leading peer-reviewed journals, with a particular focus on the clinical development of antibodies and antibody-drug conjugates, gene and cell therapy, and hemophilia. Dr. Josephson obtained his medical degree from Columbia University and his undergraduate degree from Dartmouth College.
Pete Olson, PhD Chief Scientific Officer
Pete Olson is the Chief Scientific Officer at Iambic Therapeutics. Prior to joining Iambic's executive leadership team, Dr. Olson was the Vice President, Research at Mirati Therapeutics, a Bristol Myers Squibb (BMS) company.
AI Analysis | Feedback
- Clinical Development and Regulatory Approval Risk: Iambic Therapeutics' success hinges on its drug candidates, particularly its lead program IAM1363, successfully navigating rigorous and expensive clinical trials to demonstrate sufficient efficacy and safety, and ultimately receiving regulatory approval. There is an inherent high failure rate for drug candidates in clinical development, and even promising early-stage results may not translate into approved products, which would significantly impact the company's future revenue and viability.
- Competition and Market Acceptance Risk: Even if Iambic's drug candidates achieve regulatory approval, they will face significant competition from established rivals. For instance, IAM1363, which targets HER2, must prove its value against existing and well-entrenched treatments in the market. This competitive landscape could make it challenging to gain market share and achieve commercial success.
- Funding and Commercialization Risk: As a clinical-stage company with no approved products and a reliance on partnerships for revenue, Iambic Therapeutics experiences significant cash burn. The company will require substantial ongoing financing to fund its expensive clinical development programs and, if successful, to build the necessary infrastructure for commercializing any approved drugs. Future financing may not be available on favorable terms or at all.
AI Analysis | Feedback
AI Analysis | Feedback
- For IAM1363 (a HER2 inhibitor) and IAM-C1 (a selective dual CDK2/4 inhibitor), the company estimates addressable markets exceeding $10 billion.
- For IAM217 (a brain-penetrant, allosteric KIF18A inhibitor), the estimated addressable market is greater than $5 billion.
- Across all their discovery-stage programs, Iambic Therapeutics projects addressable markets totaling approximately $70 billion.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Iambic Therapeutics (IAM) over the next 2-3 years:
- Advancement and Potential Commercialization of Lead Product (IAM1363): Iambic Therapeutics' lead drug candidate, IAM1363, an oral, brain-penetrant HER2 inhibitor, is currently in a multi-center Phase 1/1b clinical trial for HER2-altered solid tumors. The company plans to initiate a registrational trial for IAM1363 as early as 2027. Successful progression through clinical trials and eventual market approval would be a significant source of product revenue.
- Progression of Additional Pipeline Candidates (IAM217 and IAM-C1): Iambic aims to submit Investigational New Drug (IND) applications for two other promising candidates in Q4 2026: IAM217, a KIF18A inhibitor for triple-negative breast cancer and other solid tumors, and IAM-C1, a selective CDK2/4 inhibitor for HR+/HER2- breast cancer and CCNE1 amplified cancers. The initiation of Phase 1/2 clinical trials for these programs, subject to regulatory feedback, represents future revenue potential through milestone payments and eventual commercialization.
- Expansion and Monetization of AI-Driven Drug Discovery Partnerships: Iambic has established numerous collaborations with major pharmaceutical companies, including AbbVie, Takeda, and Bayer, leveraging its proprietary "molecular superintelligence" AI platform for drug discovery across various therapeutic areas such as oncology, immunology, and neuroscience. These partnerships generate revenue through upfront payments, research service fees, and success-based milestone payments, which have been a substantial source of the company's historical revenue and are expected to continue to grow.
AI Analysis | Feedback
Share Issuance
- Iambic Therapeutics filed an S-1 with the SEC on September 21, 2026, for an initial public offering (IPO) to list on Nasdaq under the ticker "IAM", with the number of shares and price range yet to be disclosed.
- The company has raised approximately $461.8 million through private financing rounds since its inception through September 18, 2026. This includes a $53 million Series A in 2021, a $100 million Series B in October 2023, an oversubscribed financing of over $100 million in November 2025, and an additional $66 million private placement in 2026.
- Between August 14, 2026, and September 11, 2026, Iambic Therapeutics issued $66.50 million in 8.0% subordinated convertible promissory notes, which are set to automatically convert into common stock upon the IPO closing.
Inbound Investments
- Iambic Therapeutics has attracted approximately $461.8 million in capital from investors, including Catalio, Nexus Ventures, Q Healthcare Holding, NVIDIA Corporation, and Coatue Ventures, through September 18, 2026.
- The company has secured high-profile partnerships, including a multiyear deal with Takeda worth up to $1.7 billion in potential milestones signed in February 2026, and a collaboration with AbbVie.
- Upfront payments from R&D collaboration agreements include $10 million from Lundbeck, $27 million from Takeda Pharmaceutical, and $40 million from AbbVie.
Capital Expenditures
- Capital expenditures for the first half of 2026 were $1.94 million.
- The primary focus of anticipated capital expenditures from the IPO proceeds will be to support the clinical development of three programs: IAM1363, IAM217, and IAM-C1.
- Iambic's automated wet-lab workflow for microscale chemistry and biology reduces capital allocation towards commercial-scale manufacturing plants.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 13.4% | 63.7% | 103.3% | CAH 490% · MCK 391% · COR 194% |
| Health Care Services | 20 | 44.0% | 33.3% | 11.6% | HIMS 220% · RDNT 148% · DGX 96% |
| Managed Health Care | 8 | 44.6% | 5.6% | 0.6% | OSCR 107% · HQY 59% · ELV 11% |
| Health Care Facilities | 25 | 16.9% | 18.4% | -3.0% | THC 302% · NHC 241% · EHC 202% |
| Health Care Equipment | 50 | 14.4% | 18.7% | -15.0% | UFPT 408% · GKOS 348% · PLSE 147% |
| Pharmaceuticals | 60 | -5.1% | 8.2% | -35.2% | LQDA 999% · KNSA 546% · LLY 448% |
| Health Care Supplies | 11 | 34.9% | 23.0% | -36.1% | LNTH 267% · HAE 76% · MMSI 33% |
| Life Sciences Tools & Services | 108 | -6.2% | -10.3% | -74.1% | AXGN 288% · NTRA 253% · MEDP 189% |
| Biotechnology ← | 364 | -21.1% | -31.5% | -81.7% | ELVN 1112% · TRVI 1046% · DNTH 930% |
| Health Care Technology | 21 | -23.4% | -56.5% | -82.3% | VEEV -3% · DOCS -52% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 12.77 |
| Mkt Cap | 2.2 |
| Rev LTM | 67 |
| Op Inc LTM | -211 |
| FCF LTM | -130 |
| FCF 3Y Avg | -143 |
| CFO LTM | -127 |
| CFO 3Y Avg | -93 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 23.9% |
| Rev Chg 3Y Avg | 10.3% |
| Rev Chg Q | 1.0% |
| QoQ Delta Rev Chg LTM | 0.2% |
| Op Inc Chg LTM | 20.0% |
| Op Inc Chg 3Y Avg | -21.1% |
| Op Mgn LTM | -318.7% |
| Op Mgn 3Y Avg | -632.4% |
| QoQ Delta Op Mgn LTM | -1.9% |
| CFO/Rev LTM | -143.5% |
| CFO/Rev 3Y Avg | -221.9% |
| FCF/Rev LTM | -180.8% |
| FCF/Rev 3Y Avg | -373.0% |
Price Behavior
| Market Price | $13.40 | |
| Distance from 52W High | -43.7% | |
| 50 Days | 200 Days | |
| DMA Price | $4.61 | $1.15 |
| DMA Trend | up | up |
| Distance from DMA | 190.6% | 1,062.4% |
| 3M | 1YR | |
| Volatility | 44,748,992.1% | 20,864,326.3% |
| Downside Capture | ||
| Upside Capture | ||
| Correlation (S&P 500) |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 564352.12 | � | -525293.79 | � | � | � |
| Up Beta | -11128905.88 | -3445570.08 | 1736976.74 | � | � | � |
| Down Beta | -0.81 | � | 3.05 | � | � | � |
| Up Capture | 213665709% | 107209139% | 66680730% | � | � | � |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 4 | 5 | 4 | 6 | 7 | 24 |
| Down Capture | -49% | -∞% | -21% | � | � | � |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 8 | 8 | 8 | 10 | 11 | 29 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IAM | |
|---|---|---|---|---|
| IAM | -100.0% | 427.4% | -4.60 | - |
| Sector ETF (XLV) | 33.1% | 16.7% | 1.53 | 24.1% |
| Equity (SPY) | 13.2% | 12.9% | 0.68 | -8.8% |
| Gold (GLD) | 1.0% | 28.8% | 0.03 | 2.1% |
| Commodities (DBC) | 35.9% | 21.2% | 1.34 | -7.8% |
| Real Estate (VNQ) | 14.3% | 14.1% | 0.70 | 7.2% |
| Bitcoin (BTCUSD) | -28.2% | 43.4% | -0.65 | 63.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IAM | |
|---|---|---|---|---|
| IAM | -100.0% | 422.7% | -0.22 | - |
| Sector ETF (XLV) | 9.3% | 15.3% | 0.40 | -6.0% |
| Equity (SPY) | 12.5% | 17.2% | 0.55 | -10.4% |
| Gold (GLD) | 17.3% | 19.1% | 0.73 | -3.6% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | -3.8% |
| Real Estate (VNQ) | 1.8% | 18.9% | -0.01 | -8.0% |
| Bitcoin (BTCUSD) | 5.5% | 51.5% | 0.29 | 1.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IAM | |
|---|---|---|---|---|
| IAM | -100.0% | 298.0% | 0.04 | - |
| Sector ETF (XLV) | 12.5% | 16.8% | 0.61 | -1.6% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | -4.1% |
| Gold (GLD) | 11.9% | 16.5% | 0.59 | -2.6% |
| Commodities (DBC) | 7.4% | 18.1% | 0.33 | -2.0% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.23 | -2.7% |
| Bitcoin (BTCUSD) | 61.0% | 66.2% | 1.01 | 1.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 09/21/2026 | S-1 |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 09/21/2026 | S-1 |
Insider Activity
Updated 10/19/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Rachlin, Evan Lockwood | See footnote | Buy | 10192026 | 16.00 | 718,750 | 11,500,000 | 41,411,968 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Rachlin, Evan Lockwood | See footnote | Buy | 10192026 | 16.00 | 718,750 | 11,500,000 | 41,411,968 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.